170 related articles for article (PubMed ID: 17108060)
1. Effects of green tea compounds on irinotecan metabolism.
Mirkov S; Komoroski BJ; Ramírez J; Graber AY; Ratain MJ; Strom SC; Innocenti F
Drug Metab Dispos; 2007 Feb; 35(2):228-33. PubMed ID: 17108060
[TBL] [Abstract][Full Text] [Related]
2. Determination of drug interactions occurring with the metabolic pathways of irinotecan.
Charasson V; Haaz MC; Robert J
Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202
[TBL] [Abstract][Full Text] [Related]
3. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
[TBL] [Abstract][Full Text] [Related]
4. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.
Mallick P; Shah P; Gandhi A; Ghose R
Life Sci; 2015 Oct; 139():132-8. PubMed ID: 26334566
[TBL] [Abstract][Full Text] [Related]
5. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4.
Sai K; Kaniwa N; Ozawa S; Sawada JI
Drug Metab Dispos; 2001 Nov; 29(11):1505-13. PubMed ID: 11602529
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
Hirose K; Yamashita K; Takada H; Kaneda N; Fukami K; Maruo E; Kitamura M; Hasegawa J; Maeda Y
Int J Clin Oncol; 2014 Apr; 19(2):397-402. PubMed ID: 23605141
[TBL] [Abstract][Full Text] [Related]
7. Modulation of irinotecan metabolism by ketoconazole.
Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
[TBL] [Abstract][Full Text] [Related]
8. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
van Erp NP; Baker SD; Zhao M; Rudek MA; Guchelaar HJ; Nortier JW; Sparreboom A; Gelderblom H
Clin Cancer Res; 2005 Nov; 11(21):7800-6. PubMed ID: 16278402
[TBL] [Abstract][Full Text] [Related]
9. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes.
Haaz MC; Riché C; Rivory LP; Robert J
Drug Metab Dispos; 1998 Aug; 26(8):769-74. PubMed ID: 9698291
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos A; Zanetta S; Cresteil T; Deroussent A; Pein F; Raymond E; Vernillet L; Risse ML; Boige V; Gouyette A; Vassal G
Clin Cancer Res; 2000 May; 6(5):2012-20. PubMed ID: 10815927
[TBL] [Abstract][Full Text] [Related]
11. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
Gagné JF; Montminy V; Belanger P; Journault K; Gaucher G; Guillemette C
Mol Pharmacol; 2002 Sep; 62(3):608-17. PubMed ID: 12181437
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
[TBL] [Abstract][Full Text] [Related]
13. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.
Yong WP; Ramirez J; Innocenti F; Ratain MJ
Clin Cancer Res; 2005 Sep; 11(18):6699-704. PubMed ID: 16166450
[TBL] [Abstract][Full Text] [Related]
14. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
van der Bol JM; Loos WJ; de Jong FA; van Meerten E; Konings IR; Lam MH; de Bruijn P; Wiemer EA; Verweij J; Mathijssen RH
Eur J Cancer; 2011 Apr; 47(6):831-8. PubMed ID: 21216137
[TBL] [Abstract][Full Text] [Related]
15. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta E; Lestingi TM; Mick R; Ramirez J; Vokes EE; Ratain MJ
Cancer Res; 1994 Jul; 54(14):3723-5. PubMed ID: 8033091
[TBL] [Abstract][Full Text] [Related]
16. [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].
Valenzuela Jiménez B; González Sales M; Escudero Ortiz V; Martínez Navarro E; Pérez Ruixo C; Rebollo Liceaga J; González Manzano R; Pérez Ruixo JJ
Farm Hosp; 2013; 37(2):111-27. PubMed ID: 23789755
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
[TBL] [Abstract][Full Text] [Related]
18. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan.
Fujita K; Ando Y; Narabayashi M; Miya T; Nagashima F; Yamamoto W; Kodama K; Araki K; Endo H; Sasaki Y
Drug Metab Dispos; 2005 Dec; 33(12):1785-90. PubMed ID: 16123050
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of irinotecan.
Toffoli G; Cecchin E; Corona G; Boiocchi M
Curr Med Chem Anticancer Agents; 2003 May; 3(3):225-37. PubMed ID: 12769780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
